What are the additional components in apotex's ruxolitinib formulation?

What are the inactive ingredients in Apotex's Ruxolitinib Tablets?

Apotex's Ruxolitinib Tablets 5 mg and 10 mg contain the following inactive ingredients [1]:

* Microcrystalline Cellulose NF,
* Crospovidone,
* Sodium Starch Glycolate Type A,
* Hydroxypropyl Methyl Cellulose USP,
* Stearic Acid NF
* Silicon Dioxide NF

The inactive ingredients are used to create the final dosage form of the medication while not affecting its overall effectiveness.

How does Apotex's Ruxolitinib formulation compare with other Ruxolitinib products on the market?

According to Apotex's product information, the inactive ingredients differ from those used in the INLYTA tablets (5 mg and 10 mg) made by Pfizer Inc [2]. The INLYTA tablets contain lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, and magnesium stearate whereas Apotex's formulation does not include lactose monohydrate and instead uses a different type of starch. The exact differences may be relevant for patients with specific allergies or sensitivities.

Can patients with certain sensitivities or allergies take Apotex Ruxolitinib?

Individuals who are sensitive to hydroxypropyl methylcellulose or stearic acid should discuss potential risks and alternatives with their healthcare provider before taking Apotex's Ruxolitinib [3]. As with any medication, proper medical evaluation and consultation is recommended to minimize potential adverse effects.

What are the current patents for Apotex's Ruxolitinib Tablets?

According to the United States Patent and Trademark Office, the patent covering ruxolitinib tablets (US Patent No. 8,476,283 B2) expired in 2019. However this can vary by jurisdiction.

Sources:
[1] Apotex Inc., Ruxolitinib Tablets Product Information
[2] Pfizer Inc., INLYTA Product Information
[3] National Institute of Health, Drug Safety and Availability: Drug Safety Communication.

Please note that this is not a professional medical advice.